Concepts (122)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Blood Group Incompatibility | 3 | 2016 | 11 | 0.970 |
Why?
|
| ABO Blood-Group System | 3 | 2016 | 21 | 0.970 |
Why?
|
| Kidney Transplantation | 3 | 2016 | 515 | 0.830 |
Why?
|
| Erythrocytes | 3 | 2017 | 45 | 0.830 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2020 | 9 | 0.650 |
Why?
|
| Blood Preservation | 2 | 2017 | 10 | 0.540 |
Why?
|
| Medical Waste | 1 | 2017 | 2 | 0.530 |
Why?
|
| Cold Temperature | 1 | 2017 | 61 | 0.520 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2015 | 4 | 0.450 |
Why?
|
| Herpesvirus 4, Human | 1 | 2015 | 9 | 0.450 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2015 | 11 | 0.440 |
Why?
|
| Erythrocyte Transfusion | 5 | 2020 | 35 | 0.440 |
Why?
|
| Autoantibodies | 1 | 2015 | 52 | 0.430 |
Why?
|
| HLA Antigens | 1 | 2014 | 43 | 0.410 |
Why?
|
| Cryopreservation | 2 | 2010 | 55 | 0.370 |
Why?
|
| Hypersensitivity | 2 | 2008 | 26 | 0.330 |
Why?
|
| Fever | 2 | 2008 | 63 | 0.330 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2010 | 112 | 0.330 |
Why?
|
| Kidney Failure, Chronic | 1 | 2014 | 548 | 0.310 |
Why?
|
| Troponin | 2 | 2020 | 114 | 0.300 |
Why?
|
| Immunization | 1 | 2009 | 40 | 0.290 |
Why?
|
| Autoimmunity | 1 | 2009 | 34 | 0.290 |
Why?
|
| Diphenhydramine | 1 | 2008 | 3 | 0.290 |
Why?
|
| Histamine H1 Antagonists | 1 | 2008 | 9 | 0.290 |
Why?
|
| Premedication | 1 | 2008 | 17 | 0.280 |
Why?
|
| Acetaminophen | 1 | 2008 | 20 | 0.280 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2008 | 67 | 0.270 |
Why?
|
| Humans | 17 | 2020 | 34474 | 0.250 |
Why?
|
| Anemia, Hemolytic | 1 | 2005 | 9 | 0.230 |
Why?
|
| Adult | 8 | 2020 | 10015 | 0.230 |
Why?
|
| Isoantibodies | 1 | 2005 | 12 | 0.230 |
Why?
|
| Blood Donors | 2 | 2003 | 13 | 0.220 |
Why?
|
| Blood Component Removal | 1 | 2003 | 2 | 0.210 |
Why?
|
| von Willebrand Diseases | 1 | 2003 | 4 | 0.210 |
Why?
|
| Diabetic Nephropathies | 1 | 2005 | 228 | 0.210 |
Why?
|
| Factor VIII | 1 | 2003 | 25 | 0.200 |
Why?
|
| Fibrinogen | 1 | 2003 | 69 | 0.200 |
Why?
|
| Disease Transmission, Infectious | 1 | 2003 | 18 | 0.200 |
Why?
|
| Male | 9 | 2020 | 20697 | 0.190 |
Why?
|
| Blood Grouping and Crossmatching | 2 | 2016 | 9 | 0.180 |
Why?
|
| Immunoglobulin M | 1 | 2020 | 19 | 0.160 |
Why?
|
| Ambulances | 1 | 2020 | 12 | 0.160 |
Why?
|
| Transportation of Patients | 1 | 2020 | 25 | 0.160 |
Why?
|
| Blood Banks | 1 | 2017 | 7 | 0.130 |
Why?
|
| Emergency Medical Services | 1 | 2020 | 189 | 0.130 |
Why?
|
| Hospitals | 1 | 2017 | 105 | 0.120 |
Why?
|
| Platelet Transfusion | 2 | 2008 | 17 | 0.120 |
Why?
|
| Time Factors | 5 | 2020 | 2352 | 0.120 |
Why?
|
| Myocardial Infarction | 1 | 2020 | 515 | 0.120 |
Why?
|
| Hemorrhage | 2 | 2008 | 109 | 0.120 |
Why?
|
| Middle Aged | 6 | 2020 | 12703 | 0.110 |
Why?
|
| Cryoglobulins | 1 | 2015 | 5 | 0.110 |
Why?
|
| Female | 7 | 2020 | 21490 | 0.110 |
Why?
|
| Tissue Donors | 1 | 2016 | 208 | 0.110 |
Why?
|
| DNA, Viral | 1 | 2015 | 57 | 0.110 |
Why?
|
| Histocompatibility Testing | 1 | 2014 | 26 | 0.110 |
Why?
|
| Brain Death | 1 | 2014 | 27 | 0.110 |
Why?
|
| Immunoglobulin G | 1 | 2015 | 135 | 0.110 |
Why?
|
| Treatment Outcome | 2 | 2014 | 3618 | 0.100 |
Why?
|
| Graft Rejection | 1 | 2014 | 242 | 0.100 |
Why?
|
| Cardiovascular Diseases | 1 | 2020 | 1209 | 0.090 |
Why?
|
| Aged | 3 | 2020 | 10998 | 0.090 |
Why?
|
| Iron Overload | 1 | 2009 | 38 | 0.080 |
Why?
|
| Leukemia | 1 | 2009 | 43 | 0.080 |
Why?
|
| Prospective Studies | 2 | 2020 | 2461 | 0.070 |
Why?
|
| Iron | 1 | 2009 | 121 | 0.070 |
Why?
|
| Leukocyte Reduction Procedures | 1 | 2008 | 2 | 0.070 |
Why?
|
| Blood Component Transfusion | 1 | 2008 | 11 | 0.070 |
Why?
|
| Blood Transfusion | 1 | 2009 | 76 | 0.070 |
Why?
|
| Plasma | 1 | 2008 | 15 | 0.070 |
Why?
|
| Stem Cell Transplantation | 1 | 2009 | 228 | 0.070 |
Why?
|
| Drug Administration Schedule | 1 | 2008 | 306 | 0.070 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 318 | 0.070 |
Why?
|
| Double-Blind Method | 1 | 2008 | 597 | 0.060 |
Why?
|
| Leukapheresis | 2 | 2004 | 3 | 0.060 |
Why?
|
| Wounds and Injuries | 1 | 2008 | 242 | 0.060 |
Why?
|
| Rho(D) Immune Globulin | 1 | 2005 | 2 | 0.060 |
Why?
|
| Glycosuria, Renal | 1 | 2005 | 3 | 0.060 |
Why?
|
| Hemolysis | 1 | 2005 | 12 | 0.060 |
Why?
|
| Lymphocytes | 1 | 2005 | 59 | 0.060 |
Why?
|
| Transplantation, Homologous | 1 | 2005 | 163 | 0.060 |
Why?
|
| Risk Factors | 2 | 2020 | 4136 | 0.050 |
Why?
|
| Infant, Newborn | 2 | 2003 | 730 | 0.050 |
Why?
|
| Circumcision, Male | 1 | 2003 | 4 | 0.050 |
Why?
|
| Parasitic Diseases | 1 | 2003 | 5 | 0.050 |
Why?
|
| Blood-Borne Pathogens | 1 | 2003 | 7 | 0.050 |
Why?
|
| Fathers | 1 | 2003 | 13 | 0.050 |
Why?
|
| Plasma Exchange | 1 | 2003 | 14 | 0.050 |
Why?
|
| Virus Diseases | 1 | 2003 | 22 | 0.050 |
Why?
|
| Bacterial Infections | 1 | 2003 | 51 | 0.050 |
Why?
|
| Stem Cell Factor | 1 | 2001 | 13 | 0.040 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 2001 | 27 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2001 | 60 | 0.040 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2001 | 103 | 0.040 |
Why?
|
| Neoplasms | 1 | 2008 | 791 | 0.040 |
Why?
|
| Cell Separation | 1 | 2001 | 93 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2003 | 922 | 0.040 |
Why?
|
| Point-of-Care Systems | 1 | 2020 | 46 | 0.040 |
Why?
|
| Adolescent | 1 | 2008 | 3799 | 0.040 |
Why?
|
| Macaca mulatta | 1 | 2001 | 355 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 612 | 0.040 |
Why?
|
| Survival Analysis | 2 | 2009 | 509 | 0.030 |
Why?
|
| Mice | 1 | 2001 | 2691 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2020 | 1506 | 0.030 |
Why?
|
| Cell Division | 2 | 2001 | 99 | 0.020 |
Why?
|
| Anemia, Aplastic | 1 | 2009 | 5 | 0.020 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2009 | 27 | 0.020 |
Why?
|
| Trauma Centers | 1 | 2008 | 88 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2008 | 3812 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2009 | 703 | 0.020 |
Why?
|
| Research Design | 1 | 2009 | 337 | 0.020 |
Why?
|
| Prognosis | 1 | 2009 | 1603 | 0.010 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 2001 | 7 | 0.010 |
Why?
|
| Umbilical Veins | 1 | 2001 | 15 | 0.010 |
Why?
|
| E-Selectin | 1 | 2001 | 21 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 2001 | 28 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2001 | 60 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2001 | 103 | 0.010 |
Why?
|
| Incidence | 1 | 2004 | 1288 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2001 | 163 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2001 | 834 | 0.010 |
Why?
|
| Animals | 1 | 2001 | 8544 | 0.000 |
Why?
|